San Diego-based Illumina (NASDAQ: ILMN) has announced that its CFO, Sam Samad, will be leaving the company next month.
“Sam Samad will be departing Illumina on July 8, 2022, after serving as CFO for more than five years,” said a release issued late Thursday.
Samad was named SDBJ’s CFO of the Year in the large business category in 2022.
Illumina, a global leader in DNA sequencing and array-based technologies, said Joydeep Goswami, the company’s current chief strategy and corporate development officer, will also serve as interim CFO while Illumina conducts a search for a permanent CFO.
“Sam has made significant contributions to our Finance organization and the company during his time at Illumina,” said Francis deSouza, Illumina’s CEO. “I’d like to thank him for his leadership and wish him every success in his future role. As we execute our CFO search, I am grateful for Joydeep’s deep global business experience and collaboration with our strong Finance leadership team. He is an established, trusted leader who will bring both strategic and operational mindsets to drive shareholder value.”
Prior to joining Illumina, Goswami had more than a decade of senior management and P&L; responsibilities at Thermo Fisher Scientific, and previously served pharma, technology, and private equity clients at McKinsey & Company. He holds an M.S., Ph.D. in chemical engineering, and an MBA from the Massachusetts Institute of Technology as well as a bachelor’s degree in chemical engineering from the Indian Institute of Technology, Mumbai.